The anemia associated with chronic renal failure is one of the best target diseases for erythropoietin (Epo) gene transfer. We previously reported a short-term (1 month) study of continuous rat Epo delivery by muscle-targeted gene transfer of plasmid DNA expressing rat Epo (pCAGGS-Epo) using in vivo electroporation in normal rats. Here, we performed a long-term pharmacokinetic study of continuous Epo delivery by this method in normal rats and uremic five-sixths nephrectomized rats. In normal rats, Epo gene expression and sufficient erythropoiesis occurred with Epo gene transfer in a dose-dependent manner, and persisted for at least 11
Introduction
Erythropoietin (Epo) is a survival factor for erythroid progenitor cells, preventing their apoptosis. 1 Thus, to obtain sustained Epo levels, a gene therapy system providing continuous delivery may be more effective than an intermittent one. The skeletal muscle is a convenient target for direct plasmid DNA transfer aimed at delivering therapeutic proteins systemically with a high degree of safety. 2 Although plasmid vectors are inefficiently taken up by muscle cells and manifest relatively low-level expression compared with viral vectors, 3, 4 they still have several advantages over viral vectors. A large quantity of highly purified plasmid DNA is easily and inexpensively obtained. Gene transfer can be repeated without apparent immune responses to the DNA vector. Moreover, it was recently demonstrated that in vivo electroporation after intramuscular DNA injection greatly enhances gene transfer into mouse muscles. 5 We have previously showed that Epo gene transfer into muscle by in vivo electroporation sustained a hematocrit increase for about 1 month in the normal rat, which is more than 10 times larger than the mouse. 6 In our earl- weeks. Repeated administration of the plasmid DNA effectively produced erythropoiesis. Similar erythropoiesis was observed in the uremic rats, and persisted for more than 15 weeks. Both normal and uremic rats showed a significant decrease in platelet count. Moreover, the uremic rats showed Epo-induced hypertension, which is the major sideeffect of recombinant human Epo. These results demonstrate that muscle-targeted pCAGGS-Epo transfer by in vivo electroporation is a useful procedure for the long-term continuous delivery of Epo in both normal and uremic rats. Gene Therapy (2001) 8, 461-468.
ier study, we did not examine the duration of the Epo expression, the dose dependency of the hematocrit levels, the effect of readministration of plasmid DNA on erythropoiesis, or the side-effects of long-term bone marrow stimulation caused by Epo, especially the consequences of the decrease in platelet count observed at the end of the previous short-term experiment. 6 The current major indication for recombinant human (rHu) Epo is the anemia associated with chronic renal failure. The major side-effects of rHuEpo therapy are an increase in blood pressure, known as rHuEpo-induced hypertension 7, 8 and a decline in renal function in uremic patients 9 and rats. 10 Most of the previous studies of Epo gene transfer have been performed on normal mice or rats. There have been only three reports on the feasibility of Epo gene therapy for treating the anemia associated with chronic renal failure in animal models. [11] [12] [13] Consequently, the above-mentioned side-effects have not been examined in previous studies of Epo delivery by gene transfer. Therefore, it is important to assess the physiological effects of Epo gene expression in a model of anemia associated with chronic renal failure.
In the present study, we evaluated the long-term effects of expressing the Epo gene in the muscles of normal and uremic rats by using injection followed by in vivo electroporation to deliver pCAGGS-Epo, an Epo expression plasmid vector. 6 This muscle-targeted gene transfer produced physiologically significant levels of Epo in the systemic circulation and increased erythropoiesis in both normal and uremic rats. Moreover, some of the side-effects were clarified as follows: the decrease in platelet count was seen in both normal and uremic rats, and Epo-induced hypertension, the progression of renal dysfunction, and growth disturbance were seen only in uremic rats.
Results
Pharmacokinetics of serum Epo levels of normal rats (Figure 1a ) Rats were assigned to five groups: four groups were subjected to Epo gene transfer using in vivo electroporation with either 400 g of pCAGGS-Epo (pCAGGS-Epo 400 g rats; n = 7), 30 g of pCAGGS-Epo (pCAGGS-Epo 30 g rats; n = 8), 10 g of pCAGGS-Epo (pCAGGS-Epo 10 g rats; n = 7), or 400 g of pCAGGS (control rats; n = 7), and one group was subjected to a simple injection of 400 g of pCAGGS-Epo (simple injection rats; n = 7).
The serum Epo levels in the simple injection rats and the control rats were not significantly increased. However, after injection with in vivo electroporation of 400 g of pCAGGS-Epo, the serum Epo levels peaked at 114.7 ± 15.8 mU/ml at week 1, gradually decreased to 35.7 ± 5.4 mU/ml at week 11, and persisted at around 25 mU/ml after week 14. Until week 11, a similar pattern was obtained using smaller doses of plasmid, 10 or 30 g of pCAGGS-Epo, even though the increase of the serum Epo levels was not statistically significant. These data indicate that continuous delivery of Epo for more than 11 weeks in rats can be achieved by muscle-targeted gene transfer using in vivo electroporation.
Red blood cell (RBC) analysis in normal rats
Vector-derived Epo secretion caused reticulocytosis (Figure 1b) . Reticulocytes significantly increased in rats injected with more than 10 g of pCAGGS-Epo followed by in vivo electroporation. In each group, the time-course of reticulocyte levels bore a striking resemblance to that of serum Epo levels. In fact, there was a direct correlation between the serum Epo levels and the reticulocyte levels for the subsequent 11 weeks following injection in rats receiving 400 g (n = 42, r 2 = 0.62, P = 0.0082), 30 g (n = 48, r 2 = 0.855, P Ͻ 0.0001), and 10 g (n = 42, r 2 = 0.62, P Ͻ 0.0001) of pCAGGS-Epo.
Additionally, the hematocrit level was significantly higher in the rats injected with more than 10 g of pCAGGS-Epo than in the pCAGGS-injected controls, for at least 11 weeks (Figure 1c) . The hematocrit level increased rapidly until week 5, and remained at peak levels until week 11, after which it fell, but remained higher than control levels. Thus, muscle-targeted pCAGGS-Epo plasmid transfer by in vivo electroporation continuously produced biologically active Epo, resulting in a significant elevation of the hematocrit in a dose-dependent manner.
Induction of endogenous Epo production by phlebotomy
We tested the recovery of the rats from the down-regulation of endogenous Epo production at week 11 ( Figure  2 ). Three rats from each group were used. The induction of endogenous Epo production was clearly confirmed by a significant elevation in serum Epo levels after phle- botomy in the control rats (P Ͻ 0.05), pCAGGS-Epo 10 g rats (P Ͻ 0.01), and simple injection rats (P Ͻ 0.05). Similarly, pCAGGS-Epo 30 g rats showed a tendency to increase endogenous Epo production after phlebotomy (P = 0.07). On the other hand, continuous Epo delivery by 400 g of pCAGGS-Epo resulted in the down-regulation of endogenous Epo induction (P = 0.42) even after phlebotomy, consistent with previous reports by us 6 and another group. 14 These data indicate that a sufficient dose of pCAGGS-Epo down-regulated the endogenous Epo production for as long as 11 weeks and that erythrocytosis induction was mediated by vector-encoded Epo secretion, although there is another possibility that increased endogenous Epo synthesis occurred in phlebotomized animals but overall levels of Epo protein, endogenous plus ectopic, were not detected because of Epo clearance or excretion. The rats were immediately killed after this phlebotomy experiment. Thus, the number of rats in each group in the following experiment was reduced by three.
Effect of pCAGGS-Epo readministration in normal rats
The readministration of pCAGGS-Epo is an important issue, because repeated therapy or dose escalation is required to treat the anemia associated with chronic renal failure in humans. As shown in Figure 1a , 13 weeks after the first DNA injection, we administered 400 g of pCAGGS-Epo into rats previously injected with 10 g (n = 4) or 30 g (n = 5) of pCAGGS-Epo. The other rat groups were left untreated (n = 4, respectively).
After readministration, the serum Epo levels in the pCAGGS-Epo 10 g rats peaked at 55.3 ± 10.8 mU/ml 1 week later, and gradually decreased to 22.9 ± 1.8 mU/ml after 11 weeks. In pCAGGS-Epo 30 g rats, the serum Epo levels peaked at 74.6 ± 9.4 mU/ml 1 week later, and gradually decreased to 26.3 ± 3.0 mU/ml after 11 weeks. Subsequent reticulocytosis ( Figure 1b ) and increased hematocrit levels ( Figure 1c ) were also observed. 
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Renal function and systolic blood pressure in normal rats The serum creatinine levels in each group showed sharp fluctuations within the narrow normal range, 0.5-0.7 mg/dl, but were not significantly different among the five groups throughout the experimental period (data not shown). Systolic blood pressure levels in each group showed sharp fluctuations within 115-145 mmHg, but were not significantly different among the five groups until week 11 ( Figure 3) . Thus, treatment with pCAGGSEpo resulted in significant increases in Epo and hematocrit levels, but had no adverse effects on either the serum creatinine levels or the systolic blood pressure in normal rats.
Platelet count in normal rats (Figure 4)
The platelet counts of the rats injected with 10 g or 400 g of pCAGGS-Epo were lower than for the control rats. The platelet count of pCAGGS-Epo 400 g rats decreased from preinjection levels of 85.5 ± 4.0 × 10 4 /l to 74.2 ± 4.9 × 10 4 / l at week 5, and thereafter were sustained at that level with only slight fluctuations. Similarly, the platelet count of pCAGGS-Epo 10 g rats was decreased by the readministration of 400 g of plasmid, from 86.3 ± 3.8 × 10
4 /l at week 11 to 71.3 ± 5.1 × 10 4/ l at week 16, and thereafter remained low. These results demonstrate that Epo delivery by gene transfer decreased the platelet count in a dose-dependent manner.
White blood cell (WBC) in normal rats
There was no difference in the WBC levels between the control rats and the other four groups of normal rats throughout the experimental period (data not shown).
Serum ferritin profile in normal rats
Because iron deficiency is the most common cause of resistance to Epo therapy, the serum ferritin profiles were regularly monitored. Serum ferritin levels in each group of normal rats were more than 410 ng/ml (data not shown). Thus, iron storage appeared adequate throughout the experimental period.
Growth in normal rats
All of the rats developed normally, were well nourished, and appeared to have no discomfort (data not shown). Thus, continuous Epo delivery by gene transfer did not cause growth disturbance in normal rats.
Effect of pCAGGS-Epo on uremic rats
Two weeks after the second nephrectomy, renal failure was confirmed by the development of uremia. One week later, we performed muscle-targeted transfer of plasmid DNA using in vivo electroporation in the uremic rats. Five-sixths nephrectomized rats were divided into two groups: one group was injected with 400 g of pCAGGSEpo (pCAGGS-Epo rats; n = 11) and the other with the same number of pCAGGS (control rats; n = 13). Sham nephrectomized rats were not treated with any DNA (sham rats; n = 5).
Serum Epo levels of uremic rats
After the injection of pCAGGS-Epo, the serum Epo levels increased to a maximum level of 579.8 ± 184.1 mU/ml at week 1 and gradually decreased to 46.3 ± 6.9 mU/ml at week 15 ( Figure 5a ). These data indicate that continuous delivery of Epo in uremic rats can be achieved by muscletargeted gene transfer using in vivo electroporation. Serum Epo levels in sham rats did not significantly change throughout the experimental period. There was no significant difference in serum Epo levels between control rats and sham rats during the experimental period. On the other hand, the hematocrit levels of control rats were lower than those of sham rats. These results indicate that uremic rats cannot produce an appropriate amount of endogenous Epo in response to a decrease in their hematocrit levels.
RBC analysis in uremic rats
Vector-derived Epo secretion caused marked reticulocytosis (Figure 5b) . Reticulocytes peaked at week 1, and remained significantly elevated for more than 15 weeks. There was a significant correlation between serum Epo levels and the number of reticulocytes for 15 weeks after injection (n = 57, r 2 = 0.459, P Ͻ 0.0001). The hematocrit levels of pCAGGS-Epo rats were elevated at week 1, kept gradually increasing up to week 9, and remained elevated for at least 15 weeks after electroporation (Figure 5c ).
Renal function in uremic rats
Serum creatinine levels were significantly increased 2 weeks after five-sixths nephrectomy ( Figure 6 ). Thereafter, serum creatinine further increased in both groups. The serum creatinine levels of pCAGGS-Epo rats were significantly higher than those of control rats.
Systolic blood pressure in uremic rats ( Figure 7 ) As expected, the systolic blood pressure in sham rats remained unchanged, with values maintained at 120-140 mmHg throughout the experimental period. Compared with the sham rats, the systolic blood pressure in control rats had increased by 2 weeks after the five-sixths nephrectomy and remained at even higher levels thereafter. The systolic blood pressure in pCAGGS-Epo rats increased to more than 160 mmHg by 3 weeks after in vivo electroporation and remained at even higher levels thereafter. The systolic blood pressure levels in pCAGGSEpo rats were more than 20 mmHg higher than those seen in control rats from 3 to 10 weeks after in vivo electroporation.
Platelet count in uremic rats
The platelet count of the pCAGGS-Epo rats was significantly lower than that of the control rats after week 3 or that of sham rats 7 weeks after in vivo electroporation (Figure 8 ). The platelet count of the control rats was higher than that of sham rats after in vivo electroporation.
White blood cell (WBC) in uremic rats
WBCs of the three groups of uremic rats were influenced by the invasiveness of the operation. Compared with the Gene Therapy
Figure 7 Effects of pCAGGS-Epo transfer by in vivo electroporation on systolic blood pressure in uremic rats. Differences between groups were tested by the unpaired t test. *P Ͻ 0.05 and **P Ͻ 0.01 for comparisons with control rats (comparisons made within each time-point).

Figure 8 Effects of pCAGGS-Epo transfer by in vivo electroporation on the platelet count in uremic rats. Differences between groups were tested by the unpaired t test. *P Ͻ 0.05, ***P Ͻ 0.001, and ****P Ͻ 0.0001 for comparisons with control rats (comparisons made within each time-point).
WBCs of the sham rats, WBCs of both the control and the pCAGGS-Epo rats tended to increase after five-sixths nephrectomy, which is more invasive than the sham operation (data not shown).
Serum ferritin profile in uremic rats
Serum ferritin levels in each group of uremic rats were more than 410 ng/ml (data not shown). Thus, iron storage appeared adequate throughout the experimental period.
Growth in uremic rats
As shown in Figure 9 , the rate of weight gain was different at each time-point among the three groups. The sham rats developed properly, were well nourished, and appeared to have no discomfort. In contrast, the fivesixths nephrectomized rats developed poorly and were not well nourished. Moreover, compared with the control rats, the pCAGGS-Epo rats appeared to have discomfort due to uremia, hypertension, or polycythemia.
Discussion
Our present study demonstrates that muscle-targeted Epo gene transfer using in vivo electroporation provides sufficient and continuous long-term secretion of functional Epo, resulting in erythropoiesis in normal rats.
In mice, long-term expression of Epo can be achieved by the simple injection of 10 g of plasmid DNA. 15 A significant increase in hematocrit was observed in mice injected with more than 100 g of plasmid. 16 However, in the present study, consistent with our previous findings, 6 serum Epo did not change in rats that were simply injected with 400 g of pCAGGS-Epo without in vivo electroporation. On the other hand, statistically significant elevation of the Epo levels was not achieved by the injection of as little as 10 or 30 g of pCAGGS-Epo followed by in vivo electroporation, but the increase in hematocrit was stable and long-lasting. Gene expression for more than 11 weeks was obtained by the injection of 400 g of pCAGGS-Epo followed by in vivo electroporation.
Previous reports demonstrated that serum Epo levels and hematocrit are not linearly related to the amount of Epo delivered by gene transfer, owing to efficient catabolism of excess serum Epo, saturation of target cell receptors, and a negative feedback loop that limits the biological effects of Epo in normal animals. 17, 18 Unlike the hematocrit levels, the time course of the reticulocyte count resembled that of the serum Epo levels. Moreover, a linear relationship was detected between these parameters. This relationship has not been recognized in humans treated with intermittent rHuEpo delivery. Although it is important to monitor serum Epo levels during continuous Epo delivery by gene therapy, the test is expensive. If the linear relationship holds true for humans, we could partly substitute reticulocyte count for serum Epo levels and reduce the frequency of the testing for serum Epo levels.
After readministering 400 g of pCAGGS-Epo, the peak serum Epo levels of the pCAGGS-Epo 10 g rats were one-half of the peak levels of the pCAGGS-Epo 400 g rats, and those of pCAGGS-Epo 30 g rats reached two-thirds of that value. The lower efficiency upon readministration may be due to the rats' growth between these two injections. That is, compared with the pCAGGS-Epo 400 g rats, the readministered groups received significantly lower doses of plasmid per kg body weight: 993.1 ± 12.1 g/kg in the pCAGGS-Epo 400 g rats, 702.2 ± 40.7 g/kg in the pCAGGS-Epo 10 g rats (P Ͻ 0.0001), and 707.2 ± 20.4 g/kg in the pCAGGS-Epo 30 g rats (P Ͻ 0.0001). In addition, the efficiency of gene transfer by intramuscular injection of naked DNA may be higher in younger animals. 19 Thus, animal aging during the experiment might also account for the observed decline in Epo expression. Age is an important factor, because more than half of the patients on dialysis in Japan are older than 60. 20 Therefore, it is critical to clarify whether the muscle-targeted gene transfer using in vivo electroporation could overcome aging-associated interference. Recently, Vicat et al 21 reported that the efficiency and stability of gene expression attained using electroporation with high-voltage and short-pulse (900 V/100 s) currents are not affected by the age of the animal. Moreover, there remains the possibility of immunologic responses against pCAGGS-Epo.
Compared with pCAGGS-Epo 400 g rats, uremic rats injected with the same dose showed a higher secretion of Epo. The difference may be due to growth disturbance in the uremic rats. Uremic rats received significantly higher doses of plasmid per kg body weight than normal rats: 1309.5 ± 23.6 g/kg versus 993.1 ± 12.1 g/kg, respectively, in pCAGGS-Epo 400 g rats (P Ͻ 0.0001). The difference may also result from a lower excretion of Epo due to renal dysfunction in uremic rats.
Until now, there were only three reports on the continuous delivery of Epo in uremic animals by Epo gene transfer, ex vivo with a plasmid vector 11 or in vivo with an adenovirus vector. 12, 13 There has been no demonstration of in vivo transfer of the Epo-encoding DNA plasmid in models of anemia with chronic renal failure. Our present study also demonstrates the feasibility and potential efficiency of muscle-targeted gene transfer using in vivo electroporation in the rat model of chronic renal failure.
There are still some challenges to overcome in considering the future of Epo gene therapy. An approximately 20% decrease in the platelet count was seen in both normal and uremic rats injected with 400 g of pCAGGS-Epo. This may be due to a competition between the precursor cells of the erythrocytic and megakaryotic cell lineages at the stem cell level. 22 We could avoid or reduce this effect by administering smaller doses of the transgene. Moreover, three side-effects were observed only in the uremic rats. First, the development of hypertension or the aggravation of pre-existing hypertension was observed in uremic rats injected with pCAGGS-Epo. In fact, the Epo-induced hypertension in uremic patients has been recognized as the major side-effect ever since rHuEpo was first introduced into clinical therapy, 7, 8 with an incidence of about 35%. It has not been reported in non-uremic patients 23 or normal volunteers given rHuEpo. 24 Furthermore, experiments using a rat model of renal failure demonstrated that uremia is a necessary precondition for rHuEpo-induced hypertension 25 and enhances the blood pressure response to rHuEpo. 26 Second, the progression of renal dysfunction in uremic rats was enhanced by injection with pCAGGS-Epo, probably due to Epo-induced hypertension. The adverse effects of rHuEpo therapy in uremic rats are reported to be an increase in blood pressure and a subsequent decline in renal function. 10 Third, distinct growth disturbance was observed in uremic rats injected with pCAGGS-Epo.
Rats developing metabolic acidosis demonstrate impaired growth, lower urinary creatinine excretion (suggesting an impaired acquisition of lean body mass), and an increased 3-methylhistidine:creatinine excretion ratio (indicating a progressive increase in skeletal muscle protein catabolism). 27 Therefore, it will be important to treat Epo-induced hypertension by diet or with antihypertensive drugs during Epo gene therapy.
In conclusion, muscle-targeted pCAGGS-Epo transfer by in vivo electroporation was effectively applied to a rat model of mild anemia associated with renal failure created by five-sixths nephrectomy, as well as to normal rats for the continuous delivery of Epo. Several side-effects besides polycythemia were observed, and future Epo gene therapy will have to be performed with caution against these side-effects. These results are encouraging, but the extent to which the model resembles end-stage renal disease in humans who have severe anemia with hematocrits in the 20 to 30% range remains to be seen. To clarify whether smaller doses of pCAGGS-Epo can be effective in uremic rats, we must use this type of model animal. Our next investigation will apply this approach to a rat model of severe anemia associated with chronic renal failure.
Materials and methods
Plasmid vectors
Plasmid pCAGGS-Epo was constructed by inserting rat Epo cDNA into a unique XhoI site of the pCAGGS expression vector, 28 and prepared using a Qiagen EndoFree plasmid Giga kit (Qiagen, Hilden, Germany) as previously described. 6 The empty pCAGGS plasmid was used as a control. Immediately before injection, the DNA was diluted in phosphate-buffered saline to appropriate concentrations according to the injection dose: 400 g (1.0 g/l), 30 g (0.3 g/l), and 10 g (0.1 g/l).
Rats
Eight-week-old male (first experiment: pharmacokinetics of normal rats) or 6-week-old male (second experiment: uremic rats) Wistar rats were purchased from Charles River (Tokyo, Japan). Rats were maintained under specific pathogen-free conditions in our animal facility with temperature and humidity control and a 12-h dark/light cycle before any experimental intervention. All animals were fed a standard rat chow (MF, Oriental Yeast, Tokyo, Japan) containing 23.8% protein, 0.24% sodium, and 0.0154% iron. Food and untreated tap water were available ad libitum.
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Five-sixths nephrectomy and sham nephrectomy Rats were subjected to five-sixths nephrectomy or sham nephrectomy by a two-stage surgical procedure, according to the method of Anagnostou et al. 29 Under general anesthesia with diethylether, the left kidney was exposed through a flank incision and decapsulated, and the upper and lower poles (two-thirds of the left kidney) were resected. One week later, the right kidney was resected, after which the animal had only one-sixth of the original renal mass. Sham nephrectomy consisted of decapsulation of the kidneys twice, performed at the same times as the five-sixths nephrectomy.
Intramuscular DNA injection and electroporation Muscle-targeted gene transfer by in vivo electroporation was performed essentially as previously described. 6 A total of 400 g of plasmid DNA was injected into the medial and lateral sides of each lower leg (100 g per each site). Smaller doses of pCAGGS-Epo such as 30 g or 10 g were similarly injected into the lateral side of the left lower leg. Except for muscle contractions, no abnormal reactions related to the electroporation treatment, eg cardiac arrest, were observed either during or after the procedure.
Blood parameters
Under general anesthesia, blood samples (2.0 ml) were obtained from the heart according to the method of Ohwada. 30 Serum rat Epo levels were determined using a Recombigen EPO kit (Nippon, Chiba, Japan), which is a radioimmunoassay with a rabbit polyclonal antibody against Epoetin ␣. This kit has a linear range of measurement between 3.0 and 200 mU/ml of human Epo with a detection threshold of 3.0 mU/ml. RBC, hematocrit, hemoglobin, WBC and platelet counts were measured using a Sysmex SE-9000 electronic counter (Sysmex, Hyogo, Japan). Reticulocytes were determined using a Sysmex R-3500 (Sysmex). Serum ferritin was measured by Pana-test Rat Ferritin (Panapharm Laboratories, Kumamoto, Japan). Serum creatinine was measured by Daiyaauto Crea reagent (Daiya Shiyaku, Tokyo, Japan) with an AU5200 spectrophotometer (Olympus, Tokyo, Japan).
Systolic blood pressure measurement
To evaluate the Epo-induced hypertension, we measured the systolic blood pressure (average of three consecutive measurements) of rats by the tail-cuff method after warming and slight restriction in a rat-holder using a programmable sphygmotonometer (BP-98; Softron, Tokyo, Japan). 31 Endogenous Epo production by phlebotomy We examined the effects of Epo delivery on endogenous Epo production at 11 weeks after in vivo electroporation. Three normal rats from each group were used. The rats were made anemic by phlebotomy (a blood volume equal to 1% of the body weight, ie 16% of the total blood volume was removed). 32, 33 Twenty-four hours later, the animals were bled for Epo measurement.
Statistical analysis
Data are presented as mean values ± standard error of the mean. All data were analyzed by the StatView statistical program for Macintosh (SAS, Cary, NC, USA). Statistical significance was evaluated by the unpaired t test. Corre-lation was assessed by linear regression analysis. P values of Ͻ0.05 were considered to be of significance.
